These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22343232)

  • 1. First-line chemotherapy in epithelial ovarian cancer.
    Bookman MA
    Clin Obstet Gynecol; 2012 Mar; 55(1):96-113. PubMed ID: 22343232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
    Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update of randomized trials in first-line treatment.
    Bookman MA
    Ann Oncol; 2011 Dec; 22 Suppl 8():viii52-viii60. PubMed ID: 22180402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
    Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
    Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
    Matsumoto K; Onda T; Yaegashi N
    Jpn J Clin Oncol; 2015 May; 45(5):408-10. PubMed ID: 25765457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
    Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
    J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    Gallego A; Ramon-Patino J; Brenes J; Mendiola M; Berjon A; Casado G; Castelo B; Espinosa E; Hernandez A; Hardisson D; Feliu J; Redondo A
    Clin Transl Oncol; 2021 Mar; 23(3):536-542. PubMed ID: 32651885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
    Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
    Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.
    Chou HH; Chen WC; Yang LY; Huang HJ; Chang WY; Lin H; Wu RC; Chen MY; Qiu JT; Huang KG; Chao A; Chang TC; Lai CH
    Eur J Obstet Gynecol Reprod Biol; 2021 Jul; 262():13-20. PubMed ID: 33984725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gouy S; Ferron G; Glehen O; Bayar A; Marchal F; Pomel C; Quenet F; Bereder JM; Le Deley MC; Morice P
    Gynecol Oncol; 2016 Aug; 142(2):237-42. PubMed ID: 27246305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.
    Salani R; O'Malley DM; Copeland LJ; Cohn DE; Backes FJ; Fowler JM; Eisenhauer EL
    Int J Gynecol Cancer; 2014 May; 24(4):682-6. PubMed ID: 24651631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
    Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
    Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
    Li Y; Yang Y; Shang YM; Zheng H
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.